Discovery of novel antibiotic targets in bacterial priority pathogens

Read full text Summarise with VIRAT
Authors: J.P.V. Pols
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Antimicrobial resistance is one of the biggest threats to human health worldwide in the coming decennia. While resistant bacteria are on the rise, no new antibiotic classes have passed clinical trials since the 1980s. Additionally, covalent inhibitors that bind irreversibly with their protein targets are underrepresented in drugs; with careful screening, these structures possess many advantages over conventional drugs. This thesis aimed to discover protein targets that are essential for bacterial survival, with the application of covalent irreversible inhibitors, for the discovery of novel antibiotics. A library of 10,000 compounds was tested for antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), Neisseria gonorrhoeae, and Mycobacterium tuberculosis. Selections of compounds with antibacterial activity were then used to elucidate their protein targets. For the different bacteria, different choices and different follow-up experiments, from validations to structure-activity relationship studies, were performed. For each bacterium, compounds with antibacterial activity were identified as well as essential protein targets. This research has expanded on the field of antibiotic research with a clear workflow and numerous starting points for the development of covalent inhibitors as antibiotics for pathogenic bacteria.

Fields of Study & Subjects

Computational Drug Discovery Methods Antibiotic Resistance in Bacteria Synthesis and Biological Evaluation

Publication details

Journal / source
Leiden Repository (Leiden University)
Publication date
26 March 2026
Language
EN
Document type
Thesis